Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
July 09, 2015 13:47 ET
|
Genmab A/S
Company Announcement
Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
Completion of submission triggers USD 15 million milestone...
Genmab meddeler, at der er indsendt registreringsansøgning for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL i Europa
July 07, 2015 07:29 ET
|
Genmab A/S
Selskabsmeddelelse
Ansøgning om at udvide indikationsområdet for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL indsendt af Novartis til EMA
Ansøgningen er baseret på data...
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
July 07, 2015 07:29 ET
|
Genmab A/S
Company Announcement
Application to broaden label for ofatumumab as maintenance therapy in relapsed CLL submitted to EMA by Novartis
Submission based on data from interim results of Phase...
Articles of Association for Genmab A/S
June 23, 2015 11:22 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated June 11, 2015. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel Curtis...
Selskabsvedtægter for Genmab A/S
June 23, 2015 11:22 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 11. juni 2015 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Grant of Warrants to Genmab Employees
June 11, 2015 15:44 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; June 11, 2015 – Genmab A/S (OMX: GEN) announced today that at a board meeting the board decided to issue 11,100 warrants to employees of the company as...
Tildeling af warrants til medarbejdere i Genmab
June 11, 2015 15:44 ET
|
Genmab A/S
Selskabsmeddelelse
København, Danmark, 11. juni 2015 – Genmab A/S (OMX: GEN) offentliggjorde i dag, at på et bestyrelsesmøde har bestyrelsen besluttet at tildele 11.100 warrants...
Genmab offentliggør starten på en løbende registreringsansøgning (Rolling Biologics License Application) til FDA for daratumumab i dobbelt-refraktær myelomatose
June 05, 2015 11:44 ET
|
Genmab A/S
Selskabsmeddelelse
Janssen Biotech, Inc. indleder løbende BLA-ansøgning til FDA i USA for daratumumab til behandling af dobbelt-refraktær myelomatose
Ansøgningen er baseret på...
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
June 05, 2015 11:44 ET
|
Genmab A/S
Company Announcement
Janssen Biotech, Inc. initiates rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma
Submission based on data from Phase II...
Genmab to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
June 02, 2015 09:54 ET
|
Genmab A/S
Media Release
Copenhagen, Denmark; June 2, 2015 – Genmab A/S (OMX: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 36th Annual...